Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
Open Access
- 1 June 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (6), 1038-1045
- https://doi.org/10.1373/clinchem.2007.099747
Abstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment. Methods: We developed a sandwich ELISA using recombinant human PCSK9 protein and 2 affinity-purified polyclonal antibodies directed against human PCSK9. We measured circulating PCSK9 concentrations in 115 diabetic patients from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study before and after fenofibrate treatment. Results: We found that plasma PCSK9 concentrations correlate with total (r = 0.45, P = 0.006) and LDL (r = 0.54, P = 0.001) cholesterol but not with triglycerides or HDL cholesterol concentrations in that cohort. After 6 weeks of treatment with comicronized fenofibrate (200 mg/day), plasma PCSK9 concentrations decreased by 8.5% (P = 0.041 vs pretreatment). This decrease correlated with the efficacy of fenofibrate, as judged by a parallel reduction in plasma triglycerides (r = 0.31, P = 0.015) and LDL cholesterol concentrations (r = 0.27, P = 0.048). Conclusions: We conclude that this decrease in PCSK9 explains at least in part the LDL cholesterol–lowering effects of fenofibrate. Fenofibrate might be of interest to further reduce cardiovascular risk in patients already treated with a statin.Keywords
Funding Information
- National Health and Medical Research Council
This publication has 28 references indexed in Scilit:
- Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9Journal of Lipid Research, 2008
- Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL CholesterolClinical Chemistry, 2007
- Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activityBiochemical Journal, 2007
- The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARαToxicological Sciences, 2007
- Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosisJournal of Lipid Research, 2007
- The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLRTraffic, 2007
- Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaNature Structural & Molecular Biology, 2007
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJCI Insight, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences of the United States of America, 2005